Recursion Pharmaceuticals

Forecast & Rating8 analysts currently cover Recursion Pharmaceuticals, with about 37.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $7.22, about 122.7% upside from the current price of $3.24. Price targets range from $4.00 to $10.00 — a wide spread, showing clear disagreement over just how much Recursion Pharmaceuticals can rise. Historically, about 48.1% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Recursion Pharmaceuticals's outlook. Data as of Aug 17, 2026; for reference only and not investment advice.